Visual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling?

Rostron, Egle; McKibbin, Martin

doi:10.1038/eye.2012.61

Cited by 23 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly reductions in the rates of disability from n-AMD are now being observed at a population level in various developed economies such as Denmark, 1 Israel 2 and in regions of the United Kingdom where such data has been tracked or audited. 3,4 The overall effectiveness of anti-VEGF therapies in n-AMD is unquestionable. However, not all patients benefit in an identical manner and, as such, there have been multiple attempts to group and characterise patients' responses based on both functional and morphological outcomes.…”

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

256

227

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

256

227

View full text Add to dashboard Cite

“…1 The scheme does highlight the potential benefits in the current burden of waiting times and costs on the NHS since the introduction of the NICE guidelines. Interestingly, there was no mention of angle closure suspects in this report.…”

mentioning

confidence: 99%

Caution needed when examining certificate of vision impairment rates: the new public health indicator

Rees

Bunce

Patel

2013

Eye

View full text Add to dashboard Cite

Sir, Caution needed when examining certificate of vision impairment rates: the new public health indicatorWe read with interest the paper by Rostron and McKibbin 1 suggesting a possible fall in certificate of vision impairment (CVI) due to age-related macular degeneration (ARMD) in Leeds. It demonstrates the potential value in exploring variation in CVI rates across the country. As readers are aware the CVI is a public health indicator for vision in the newly launched Public Health Outcomes Framework, 2 so there is added interest in these figures. We feel that it is important to highlight that while CVI figures accurately describe new registrations in social service departments, it is currently unclear how this relates to disease burden as not everyone eligible for certification is certified. 3 Bunce et al 4 found that patients who require treatment for their sight impairment are almost three times less likely to be certified than those in whom treatment is not indicated. The fact that there are now new treatments for wet ARMD may mean less certifications not because of less need for social care support, but because certification can be seen to be done when no further treatment is available. Caution is needed if comparing BD8 certifications with CVI certifications, which are why the recent report by the Chief Medical Officer included CVI figures for 2007/8 as baseline. 5 When the BD8 was replaced by the CVI between 2003 and 2006, new registrations for sight impairment fell by 4000 for reasons which remain unclear, but which pre-dated widespread use of anti-VEGF drugs. This makes temporal comparisons difficult, which is why we believe focus should be on data collected from 2007 and beyond. The data reported for the period 2008 and 2010 in the paper suggests a relatively stable number of CVI registrations due to ARMD with a rise in the numbers in 2010 at a time of widespread adoption of ranibizumab therapy in the NHS. Though the incidence is reported per million population per year in the paper, it may be better to report this as a rate per million population older than 65 years of age (i.e., the at-risk population rather than total population) as in the Public Health Outcome Framework. Conflict of interestThe authors declare no conflict of interest.

show abstract

“…The introduction of this therapy into the NHS during 2008 could potentially affect future numbers of patients being registered as sight impaired. 8 This paper explores the sight-impairment certification data set further to provide detailed figures of the numbers of people certified with different types of AMD by age, sex, and ethnicity made between 1 April 2007 and 31 March 2008. The results provide a baseline measure of sight-impartment certification because of AMD at the time of introduction of ranibizumab therapy into the NHS.…”

Section: Introductionmentioning

confidence: 99%

How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration?

Rees

Zekite

Bunce

et al. 2014

Eye

View full text Add to dashboard Cite

Purpose The purpose of the study was to determine what proportion of new certifications between 1 April 2007 and 31 March 2008 could be attributed to age-related macular degeneration (AMD) and to describe the AMD-certified population in England and Wales. Methods An electronic version of the Certificate of Vision Impairment form (CVI), the ECVI, was used at the certifications office to transfer information from the paper-based certificates into a database. The electronic certifications data set was queried for all certificates completed between 1 April 2007 and 31 March 2008 with the main cause of certifiable visual loss being AMD or with the main cause of certifiable visual loss being multiple pathology but a contributory cause being AMD. The electronic data set was adapted so that a distinction could be made between geographic atrophy (GA) and neovascular AMD (nAMD). Results The Certifications Office received 23 185 CVIs between April 2007 and March 2008, of whom 9823 (42%) were people registered severely sight impaired (SSI) and 12 607 (52%) were certified as sight impaired (SI). AMD contributed to 13 000 causes of registration on the CVI forms during this period and was the main cause in 11 015 people. In these 11 015 people, GA accounted for 49.3%, nAMD 35.1%, and AMD not specified 15.7%. Conclusions The data in this report provide detailed information on CVI registration due to AMD before the widespread adoption of ranibizumab therapy in NHS practice and provide an insight into the burden of vision loss due to AMD at a time of great change in the management of nAMD.

show abstract

Visual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling?

Cited by 23 publications

References 9 publications

Defining response to anti-VEGF therapies in neovascular AMD

Defining response to anti-VEGF therapies in neovascular AMD

Caution needed when examining certificate of vision impairment rates: the new public health indicator

How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration?

Contact Info

Product

Resources

About